Elevance Health (NYSE:ELV) Price Target Raised to $449.00

Elevance Health (NYSE:ELV) had its price target raised by Morgan Stanley from $404.00 to $449.00 in a report issued on Thursday,Benzinga reports. The firm currently has an equal weight rating on the stock.

ELV has been the subject of a number of other research reports. TD Cowen boosted their price objective on Elevance Health from $400.00 to $465.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Guggenheim upped their price objective on Elevance Health from $460.00 to $485.00 and gave the company a “buy” rating in a research report on Thursday. Leerink Partners increased their target price on Elevance Health from $364.00 to $395.00 and gave the stock a “market perform” rating in a research note on Friday, July 17th. Weiss Ratings reiterated a “hold (c)” rating on shares of Elevance Health in a research report on Thursday, August 13th. Finally, UBS Group boosted their target price on shares of Elevance Health from $460.00 to $523.00 and gave the company a “buy” rating in a research note on Thursday. Fifteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $455.57.

Elevance Health Stock Down 1.2%

Shares of NYSE ELV opened at $440.05 on Thursday. Elevance Health has a 1 year low of $274.84 and a 1 year high of $450.69. The firm has a 50-day simple moving average of $408.32 and a two-hundred day simple moving average of $390.89. The company has a market cap of $95.08 billion, a P/E ratio of 18.77, a PEG ratio of 2.30 and a beta of 0.70. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.47 and a quick ratio of 1.52.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, October 21st. The company reported $6.99 EPS for the quarter, beating analysts’ consensus estimates of $4.71 by $2.28. The firm had revenue of $50.44 billion for the quarter, compared to analysts’ expectations of $49.28 billion. Elevance Health had a return on equity of 14.97% and a net margin of 2.55%. The company’s quarterly revenue was up .7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $6.03 earnings per share. Research analysts anticipate that Elevance Health will post 29.11 earnings per share for the current year.

Elevance Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be paid a $1.72 dividend. The ex-dividend date of this dividend is Friday, December 4th. This represents a $6.88 dividend on an annualized basis and a yield of 1.6%. Elevance Health’s dividend payout ratio is 29.34%.

Insider Transactions at Elevance Health

In other Elevance Health news, CFO Mark Kaye sold 10,584 shares of the stock in a transaction dated Thursday, October 22nd. The shares were sold at an average price of $440.13, for a total transaction of $4,658,335.92. Following the transaction, the chief financial officer directly owned 19,919 shares in the company, valued at $8,766,949.47. This represents a 34.70% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.34% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Elevance Health

Several hedge funds have recently modified their holdings of ELV. BlackRock Inc. purchased a new position in Elevance Health during the second quarter valued at approximately $7,344,424,000. State Street Corp raised its stake in Elevance Health by 1.3% in the second quarter. State Street Corp now owns 10,426,610 shares of the company’s stock worth $4,032,283,000 after buying an additional 137,914 shares in the last quarter. Wellington Management Group LLP raised its stake in Elevance Health by 12.0% in the second quarter. Wellington Management Group LLP now owns 9,213,513 shares of the company’s stock worth $3,563,142,000 after buying an additional 984,976 shares in the last quarter. First Eagle Investment Management LLC lifted its holdings in Elevance Health by 1.4% during the second quarter. First Eagle Investment Management LLC now owns 4,188,196 shares of the company’s stock worth $1,619,701,000 after buying an additional 55,905 shares during the period. Finally, Bank of New York Mellon Corp purchased a new stake in Elevance Health during the second quarter worth $1,246,349,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Key Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Third-quarter adjusted earnings per share rose 15.9% and exceeded consensus, while revenue also topped expectations. Elevance raised its 2026 adjusted EPS outlook to at least $29, citing disciplined cost management and improved medical-cost trends. Elevance Health Q3 Results
• Positive Sentiment: Carelon’s expansion and clinical programs remain growth drivers; its cancer program reportedly reduced avoidable inpatient admissions by 15%. Management also highlighted actions intended to improve Medicaid profitability. ELV Q3 Deep Dive
• Positive Sentiment: TD Cowen raised its price target to $495 from $465 and maintained a Buy rating, indicating continued confidence in the earnings recovery. TD Cowen Rating
• Positive Sentiment: Elevance declared a quarterly dividend of $1.72 per share, supporting its shareholder-return profile. Elevance Health Dividend
• Neutral Sentiment: Elevance appointed Jeff Park as president of Carelon in a services leadership shift. The move may support execution, but its financial impact is not yet clear. Carelon Leadership Shift
• Neutral Sentiment: Morgan Stanley lifted its target to $449 from $404 but retained an Equal Weight rating, suggesting limited upside after the recent advance. Morgan Stanley Rating
• Negative Sentiment: Officer Mark B. Kaye disclosed an intent to sell 10,584 shares valued at approximately $4.66 million. While the sale may be routine, it can weigh on sentiment near a 52-week high. Officer Share Sale
• Negative Sentiment: Analysts continue to flag sustainability risks: nine-month operating gain declined, and Medicaid margins remain under pressure. Robert W. Baird kept a Neutral rating with a $406 target, below the current trading level. Elevance Health Earnings Analysis

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.